GlassScriptPhysician profile
Lana Heath
NPI 1245437193
$6,247.16
in general payments reported to CMS, 2019-2025
49 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,268 · 2022: $2,013 · 2023: $730 · 2024: $570 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,574.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $490.53 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Galderma Laboratories, L.P. | $448.49 | 2024-2025 | Dysport |
| Novo Nordisk INC | $361.20 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $295.23 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $262.99 | 2021-2022 | |
| Pfizer INC. | $249.50 | 2021-2023 | |
| Antares Pharma, INC. | $197.00 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $194.84 | 2021-2023 | Mounjaro |
| Amarin Pharma, INC. | $190.10 | 2021-2022 | |
| Clarus Therapeutics INC. | $171.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.14 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.16 | 2022 | |
| Exact Sciences Corporation | $108.35 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $103.60 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.